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Abstract A potential means of pharmacological manage-
ment of ischemic stroke is rapid intervention using potent
neuroprotective agents. Thyroid hormone (T3) has been
shown to protect against ischemic damage in middle cerebral
artery occlusion (MCAO) model of ischemic brain stroke.
While thyroid hormone is permeable across the blood–brain
barrier, we hypothesized that efficacy of thyroid hormone in
ischemic brain stroke can be enhanced by encapsulation in
nanoparticulate delivery vehicles. We tested our hypothesis by
generating poly-(lactide-co-glycolide)-polyethyleneglycol
(PLGA-b-PEG) nanoparticles that are either coated with glu-
tathione or are not coated. We have previously reported that
glutathione coating of PLGA-PEG nanoparticles is an effi-
cient means of brain targeted drug delivery. Encapsulation of
T3 in PLGA-PEG delivery vehicle resulted in particles that
were in the nano range and exhibited a zeta potential of
−6.51 mV (uncoated) or −1.70 mV (coated). We observed
that both glutathione-coated and uncoated nanoparticles are
taken up in cells wherein they stimulated the expression of
thyroid hormone response element driven reporter robustly. In
MCAO model of ischemic stroke, significant benefit of ad-
ministering T3 in nanoparticulate form was observed over
injection of a T3 solution. A 34% decrease in tissue infarction
and a 59 % decrease in brain edema were seen upon admin-
istration of T3 solution inMCAO stroke model. Corresponding
measurements for uncoated T3 nanoparticles were 51 % and
68 %, whereas for the glutathione coated were 58 % and 75 %.
Our study demonstrates that using nanoparticle formulations
can significantly improve the efficacy of neuroprotective drugs
in ischemic brain stroke.
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Introduction
Ischemic brain stroke is one of the leading causes of death
and disability in major industrialized countries [1]. The
deadliness of stroke is compounded by (a) a limited time
window for therapeutic intervention due to a rapidly pro-
gressing pathology (approximately 3 h) and (b) lack of
viable strategies to overcome the disease pathology. Throm-
bolytic agent recombinant tissue plasminogen activator (rt-
PA) is currently the only approved agent for use in clinic.
However, thrombolysis is frequently associated with reper-
fusion injury [2]. Substantial research efforts are now fo-
cused on neuroprotective strategies, and a number of
neuroprotective agents have been suggested to improve
stroke survival and outcome in preclinical studies [3].
A significant impediment to the clinical success of
neuroprotective agents has been the efficient delivery of
the neuroprotectant agent in high enough local concen-
trations to exert protective effects [4]. Blood–brain bar-
rier (BBB) poses significant challenges to the permeation of
neuroprotective agents that exert their activity at the site of
action. Researchers recently have reported success in
overcoming BBB using nanoparticle formulations of
these drugs. In many cases, nanoparticle formulations
reported significant improvement of neuroprotective ac-
tivity of small molecules, endogenous cytokines and
proteins [5–7].
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The quest for relatively salubrious neuroprotective agents
with predictable pharmacokinetic–pharmacodynamic profile
has sparked interest in endogenous hormones for their ac-
tivity in ischemic stroke. Estrogen and its derivatives have
been a focus of tremendous interest in recent years as has
been progesterone [8, 9]. Here, we have turned attention to
thyroid hormone or L-3,5,3′-triiodothyronine (T3) as a neu-
roprotective agent.
L-3,5,3′,5′-tetraiodothyronine (T4) is a more abundant
but less active form of thyroid hormone than T3. T4 under-
goes peripheral deiodination by specific deiodinases to yield
T3, and this process is the primary source of circulatory T3.
Thyroid hormones (T3 and T4) play a crucial role in growth,
development, metabolism, and cellular energetics [10]. In
addition, thyroid hormones have profound effects on the
central nervous system. T3 is especially required in the
new neuron production and maturation during early brain
development [11, 12]. Thyroid hormone deficiency in spe-
cific time windows of brain development can lead to irre-
versible brain damage [13, 14].
Genomic actions of thyroid hormone are mediated via the
thyroid hormone receptor (TR). TR binds as a heterodimer
with retinoid X receptor (RXR) on the thyroid hormone
response element (TRE) in the promoter of its target genes
and regulates their transcriptional activity [15, 16]. Fre-
quently, TREs assume a DR4 (direct repeat 4) configuration
in which two consensus half sites are separated by four
spacer nucleotides. In the canonical mode of T3 action,
TR is bound to the TRE in the unliganded state. In this
state, TR is associated with co-repressor proteins. Upon
ligand binding, conformational change in TR occurs and
there is an increase in the affinity for coactivator proteins.
Recruitment of coactivators is associated with an increase in
the transcriptional activity of TR and modulation of target
gene expression.
Neuroprotective property of T3 has been demonstrated
previously. Non-genomic T3 activation of nitric oxide sig-
naling and vasodilation has been suggested as a possible
mechanism of neuroprotection [17]. However, other ge-
nomic mechanisms cannot be ruled out. T3 crosses the
BBB via a specific transporter called monocarboxylate
8 (MCT8). However, a significant source of T3 levels in
the brain is via deiodination of T4. We hypothesized that the
neuroprotective potential of T3 can be maximized by ad-
ministering the hormone in nanoparticulate formulations,
which would lead to consistent delivery. Poly-(lactide-co-
glycolide)-polyethyleneglycol (PLGA-b-PEG) nanopar-
ticles (NP) is an excellent carrier because of their biode-
gradability, lower toxicity, and controllable drug release rate
[18]. In our previous publication, we have demonstrated
higher brain uptake of therapeutic load in rat model using
the glutathione-coated PLGA-PEG NP [18]. Glutathione
coating is the mechanism of enhanced brain uptake of NPs
owing likely to the presence of large number of glutathione
transporters at the BBB [19–21]. Using a mouse middle
cerebral artery occlusion (MCAO) model of ischemic brain
stroke, we demonstrate here that neuroprotective property of
T3 is significantly higher in the PLGA-PEG formulations as
compared to a solution of T3. Further, the activity of the
hormone can be amplified using the glutathione-coated
PLGA-PEG particles over uncoated nanoparticles.
Materials and methods
Materials
PLGA-PEG-COOH (RESOMER® RGP d 50105, copoly-
mer ratio 50:50, PEG content 8 %) was obtained from
Boehringer Ingelheim Chemicals, Inc. (Petersburg, VA,
USA). Coumarin-6 and 2,3,5-triphenyltetrazolium chloride
(TTC) stain were obtained from Sigma-Aldrich Co. (St.
Louis, MO, USA). DMEM (Dulbecco’s modified eagle
medium), fetal calf serum, and penicillin–streptomycin were
purchased from Hyclone (Logan, UT, USA). Acetone and
acetonitrile were purchased from VWR International (Bata-
via, IL, USA). HEPES, NaCl, and EDTA were received
from VWR International (West Chester, PA, USA). Dual
luciferase kit was from Promega (Madison, WI, USA).
Preparation of glutathione-coated PLGA-PEG MP of T3
The NPs were prepared using a nanoprecipitation method as
described previously [18]. Briefly, 5 mg T3 and 120 mg
PLGA-PEG-COOH were dissolved in DMSO and mixed
together drop wise into 10 ml PBS. The NPs were stirred for
2 h at 50 °C to give a final T3 concentration of 0.5 mg/ml.
Then 20 mg glutathione was added to 1 ml NP solution
(20 mg/ml) to get 2 %w/v glutathione coating per 1 ml NP
solution and incubated at room temperature for 30 min
before use. The 6-courmarin loaded NPs were prepared
following the same protocol as that was described above.
However, 6-coumarin (in ethanol) was used instead of T3
during the procedure. The particle size and zeta potential of
uncoated and glutathione-coated PLGA-PEG NP were mea-
sured using Zetasizer (Malvern). The glutathione-coated and
uncoated NPs were also characterized by transmission elec-
tron microscopy (TEM).
Intracellular distribution of 6-coumarin-loaded MP in N2A
cells
Neuroblastoma cell line Neuro-2a (N2A) was seeded with
500 μl of DMEM containing 10 % fetal bovine serum with
penicillin (100 U/ml) and streptomycin (100 mg/ml) at
10,000 cells per well in an eight-well poly-D-lysine-coated
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chamber slide. Cells were then incubated in 5 % CO2 at 37 °C
for 24 h to achieve 70–90 % confluent cells. The medium was
aspirated and the cells were washed with PBS three
times. Then 500 μl of DMEM media containing 50
μg of 6-coumarin-loaded NP 2 % glutathione (2 %w/v
glutathione coating per 1 ml NP solution, concentration
of NP 20 mg/ml) was added to separate wells. The
cultures were then incubated in 5 % CO2 at 37 °C for
2 h. The media was aspirated after 2 h and cells were
washed three times with PBS. DAPI was added to each
well for nuclear staining and a cover slip was placed on the
chamber slide. The slide was then examined by fluorescent
microscopy with 20X magnification.
In vivo brain uptake of nanoparticles
Coumarin-6 (fluorescent dye) loaded nanoparticles were
prepared to monitor the uptake of the nanoparticles into
the ischemic brain. Procedures identical to the preparation
of T3 nanoparticles were followed with substitution of
coumarin-6 for T3. The animals were injected with
coumarin-6 NP (glutathione-coated or uncoated) via the
jugular vein in a manner similar to T3 injection. The animals
were sacrificed after 1 h. The brains were isolated and brain
slices were observed under Olympus fluorescent micro-
scope (AX70). Brain tissue was homogenized in PBS pH
7.4 and fluorescence intensity (excitation wavelength
387 nm, emission wavelength 470 nm) was measured using
BioTek microplate reader.
Luciferase assay
HepG2 cells were split at 100,000 cells/well in a 24-well
plate. The cells were transfected with DR4 X 2 luciferase
(500 ng), TRβ (200 ng), and Tk-Renilla luciferase (200 ng)
approximately 4–5 h after seeding cells. Calcium phosphate
was used to transfect cells. After about 16 h of transfection,
cells were washed with PBS and media changed to serum-
free media. Cells were treated with 100 nM T3 or 1, 10, and
100 nM of T3 nanoparticles (coated or uncoated). Cells
were harvested 24 h after T3 or vehicle treatment and dual
luciferase assay (Promega) was performed. Renilla lucifer-
ase readings were used to normalize the firefly luciferase
measurement. The data was expressed as fold change in
reporter expression by T3 or its nanoparticle formulations
over vehicle.
Ischemic brain stroke by transient middle cerebral artery
occlusion (t-MCAO)
The experiments were conducted in accordance with NIH
animal care guidelines and were approved by the Animal
Care and Use Committee at Northeast Ohio Medical
University. In vivo brain ischemia was induced as described
in detail previously [22]. Briefly, 2- to 3-month-old (25–
30 g) CD-1 male mice were subjected to 1 h of transient
middle cerebral artery occlusion (t-MCAO). Mice were
anesthetized with 1–1.5 % isofluorane in 30 % O2. Through-
out surgery, temperature was maintained at 37 °C by a
thermostatic blanket (rectal thermometer), and cerebral
blood flow was monitored by Laser Doppler flowmetry
(Moor Instruments). The skin was incised, and the left
occipital and superior thyroid arteries, branches of the ex-
ternal carotid artery (ECA) as well as the pterygopalatine
artery, branch of internal carotid artery (ICA), were exposed,
electro-coagulated, and cut. After occlusion of the common
carotid artery by microclip, the left ECA was ligated, coag-
ulated, and cut distally to the cranial thyroid artery. A 15-
mm monofilament nylon suture (6-0 Harvard Apparatus,
Holliston, MA, USA; diameter of the heat-rounded tip
0.2–0.3 mm) was inserted into the ECA and gently ad-
vanced through the ICA until its tip occluded the origin of
the MCA. Correct placement of the monofilament suture
was indicated by a sudden drop of the local cortical blood
flow in the left MCA territory to 15–20 % of basal flow as
monitored by laser Doppler flowmetry. A sustained reduc-
tion of >80 % is indicative of successful MCAO. After
successful occlusion, the monofilament was secured in place
with ligature and the skin incision was closed by ligature. To
induce transient occlusion, the monofilament was left in
place for only 60 min. Afterwards, the monofilament was
removed and the skin incision was closed by surgical clips.
For drug treatment, T3 (25 μg/kg) was injected i.v. through
the jugular vein. Equivalent doses of T3 nanoparticles in
same volume were administered to respective mice groups.
This dose of T3 elevated thyroid hormone levels but is not a
hyperthyroid dose [23]. T3, T3 nanoparticles, or vehicle
were injected 30 min before brain stroke induction. Vehicle
(PBS) treated animals served as controls. Animal cages were
placed under a medical infrared heating lamp for the first 2 h
of post-surgical recovery to prevent hypothermia as de-
scribed previously [24].
After 24 h, the animals were deeply anaesthetized with
isofluorane (4 %) and euthanized by decapitation. The
brains were quickly removed and sectioned coronally into
slices of 1 mm thickness (McIlwain Tissue Chopper). Slices
were incubated in a 1 % solution of 2,3,5-triphenyltetrazo-
lium chloride (TTC) in phosphate buffered saline at 37 °C
(water bath) for 15 min and then fixed by immersion in 4 %
buffered formaldehyde solution. TTC stains viable brain
tissue dark red based on intact mitochondrial function
[25], whereas infarcted tissue areas remain unstained
(white). Images were acquired by a digital camera (Nikon
Coolpix), and areas of both hemispheres and the infarcted
regions were quantified for each slice using image analysis
software (ImageJ, NIH). We measured the areas of ischemic
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damage (volume) as well as brain edema (ratio). Brain
edema was measured as a ratio of ipsilateral (ischemic)
hemisphere in compar i son to the cont ra la te ra l
(nonischemic) hemisphere, similar to the analyses described
by previously by us and others Elliot and Jaspar [26], and
subsequently developed by Sydserff et al. [27]. This allowed
a direct comparison of areas of damage (volume) with brain
swelling and allowed us to use each animal as its own
control in addition to inter-experimental comparisons.
Analyses were done according to a protocol adapted
from Rorden and Brett [28]. Briefly, an investigator
blinded to the animal group allocations outlined the
zones of infarction (as a clear demarcation between
stained and unstained areas) as well as the left and right
hemispheric contours seen in each digitized brain slice
picture. Three animals were used for each experiment,
and measurements were made on each slice to calculate
the volume [24] of the lesion and to correct for over-
estimation [29] due to the effects of brain swelling
where a0area of infarct (mm2), b0area of the infarcted
(ipsilateral) hemisphere slice (mm2), c0area of the non-
infarcted (contralateral) hemisphere slice (mm2), and d0
brain swelling (mm2)0(b−c). The area (Al) of the lesion
(mm2), corrected for swelling, was derived from the equation
Al0a−d. The swelling area was designated Ae and quantified
by determining the ratio between the areas of the in-
farcted and non-infarcted hemisphere slices, thus: Ae0b−c.
Infarct volume and edema ratios of hemispheric areas were
expressed as mean±standard deviation (SD) and compared
using Student’s t test. Values of P <0.05 were considered
statistically significant.
Results
The particle size distribution and zeta potential of
glutathione-coated NP containing T3 are shown in Fig. 1a
(size) and 1b (zeta potential). The uncoated NP showed
particle size and zeta potential of 304.6 nm and −6.51 mV,
respectively while glutathione-coated NP showed particle
Fig. 1 Characterization of T3 nanoparticles. a Determination of parti-
cle size of uncoated and glutathione-coated nanoparticles using Mal-
vern Zetasizer. b Determination of zeta potential of uncoated and
glutathione-coated nanoparticles using Malvern Zetasizer. c TEM im-
age showing the uncoated and glutathione-coated nanoparticles
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size and zeta potential of 326.6 nm and −1.70 mV, respec-
tively. The polydispersity indexes of both coated and un-
coated NP were less than 1, which indicated the normal
distribution or Gaussian distribution of nanoparticle size.
In this article, the uncoated T3 nanoparticles are referred
to as T3-NP and the glutathione-coated T3 nanoparticles are
referred to as T3-BTNP (T3 brain targeted NP).
TEM image shows the microstructure of the nanopar-
ticles (Fig. 1c). A size distribution in the nanometer range
was observed for all the NPs in both uncoated NP and
glutathione-coated NP samples. The glutathione coating is
seen on the right TEM image. The TEM micrographs also
reflect nearly spherical and uniform fine particles.
To investigate the intracellular uptake of therapeutic load
carried by nanoparticles, we generated courmain-6 (a fluo-
rescent dye) loaded PLGA-PEG nanoparticles that were
either glutathione-coated or uncoated. Coumarin-6 loaded
NPs were added to neuroblastoma N2A cells and their
uptake in the cells was monitored using fluorescence. DAPI
labeling was used for nucleic acid staining. Figure 2 shows
uptake of coumarin-6 in the cells as evident by the green
fluorescence in the cytoplasm. Overlay of DAPI and fluo-
rescein isothiocyanate fluorescence shows that all cells did
take up the nanoparticles. Both the coated and uncoated NPs
were equally well taken up by the cells and there was no
evident difference in fluorescence intensity in these cells.
Majority of physiological effects of T3 are attributed to
its ability to modulate expression of target genes via TR. To
evaluate whether nanoparticulate T3 retain the property to
alter gene expression, we used a cell-based transcription
assay. A luciferase reporter gene driven two repeats of
DR4 sequence was transfected in cells followed by stimu-
lation by either T3 solution or nanoparticulate T3. A renilla
luciferase vector (tk-renilla) was also transfected as an in-
ternal control. Twenty-four hours after hormone treatment,
cells were harvested and the firefly luciferase values (DR4
luciferase) were normalized to the renilla luciferase values
(tk-renilla luciferase). Fold change of normalized luciferase
values was determined over vehicle-treated samples. As
shown in Fig. 3, the nanoparticulate T3 formulations stim-
ulated the expression of the reporter just as robustly (10–20-
fold) as a T3 solution and exhibited a dose–response rela-
tionship of this response. Thus formulation of T3 as nano-
particles does not hinder its functional activity in cells in the
context of transcriptional stimulation.
Next we investigated the in vivo uptake of NPs in brain.
Mice were injected with coumarin-6 loaded 2 % glutathione-
coated or uncoated NPs i.p. at doses similar to T3 dose used
for stroke. One hour post-injection, the mice were sacrificed
and the brains were excised. Both the coated and uncoated
NPs showed accumulation in the brain. To quantify the levels
of fluorescence, the brain tissue was homogenized and fluo-
rescence intensity was measured. As shown in Fig. 4, both the
coated and uncoated coumarin NPs were taken up in the mice
brain. The coated nanoparticles showed greater uptake in the
brain than the uncoated nanoparticles, though the difference
was not statistically significant.
Finally, we tested the nanoparticle formulations of T3 for
their therapeutic benefit in ischemic stroke. Using MCAO
model of brain stroke, we tested and compared the neuro-
protective property of T3, T3-NP, and T3-BTNP. To ensure
that brain ischemia is induced by transient MCAO, we
monitored cerebral blood flow (CBF) using laser Doppler
flowmetry as described previously [22]. Individual baseline
signals obtained in each animal before induction of MCAO
were set to 100 %. As shown in Fig. 5a, MCAO induction
resulted in 80 % reduction in CBF. Animals were excluded
from the experiment if the cerebral blood flow did not
recover to at least 70 % of baseline by 10 min post-
reperfusion.
Figure 5b shows representative brain slices of the control
group as well as the T3 pre-treated group 24 h after t-
Fig. 2 In vitro cell uptake of
T3 nanoparticles. Uncoated (a)
and glutathione-coated (b)
coumarin-6 nanoparticles were
added to Neuro2A neuroblasto-
ma cells. Uptake of the nano-
particles was monitored using
fluorescence. Uptake of
coumarin-6 loaded nanopar-
ticles was detected by fluores-
cein isothiocyanate filter
(green). DAPI staining was
used for nucleic acids (blue)
and the merged overlay was
generated. Magnification
is 20X
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MCAO. Visual inspection shows that there is a striking
attenuation of the ischemic (stroke) area in those slices
treated with T3 compared with controls. This attenuation
was most visible in the cortical area (where the penumbra is
mostly located), while the internal core (where the umbra is
mostly located) was still affected by ischemia and subse-
quent cell death. Pre-treatment with T3 resulted in a reduc-
tion of focal ischemia by 34 % in comparison to vehicle-
treated control animals (statistically significant, P<0.05 ver-
sus vehicle controls) (Fig. 5c). Additionally, there was a
59 % decrease in brain swelling (edema) upon T3 pre-
treatment as compared to vehicle-treated controls (Fig. 5d).
In comparison, the nanoparticulate T3 fared significantly
better in our assays. T3-NP pretreatment resulted in a
51 % reduction of infarction and a 68 % reduction in
brain edema as compared to vehicle-treated controls. T3-
BTNP exhibited even greater efficacy in these parameters
than the T3-NPs. T3-BTNP showed a 58 % reduction of
tissue infarction and a 75 % reduction of brain edema
than the vehicle-treated controls. The difference between
T3-BTNP and T3-NP activity on these parameters was
statistically significant.
Furthermore, it was seen that the increased neuroprotec-
tive activity of nanoparticulate formulations was due to
greater efficacy in protecting the core area as was seen in
some of the stained brain slices. While the T3 solution
mainly protected the brain cortex areas from ischemic dam-
age, the brain targeted nanoparticulate T3 is able to partially
protect the core area which is most susceptible to ischemic
damage.
Discussion
In this proof-of-concept study, we have demonstrated a
means to improve the efficacy of T3 as a neuroprotective
agent in ischemic brain stroke. Using nanoparticles engi-
neered to cross the BBB, we observed that the neuroprotec-
tive efficacy of thyroid hormone can be significantly
enhanced. Thus far, nanoparticles have been suggested as
a means to facilitate the brain delivery of BBB impermeable
neuroprotectants. Our studies show that even for BBB per-
meable agents, the efficacy in a brain stroke model can be
enhanced by formulation as fine or ultrafine particles. We
show that using nanoparticles at equivalent doses, the pri-
mary pathological end-points in stroke (infarction and ede-
ma) can be improved without the need to increase the
systemic exposure of T3.
We have previously demonstrated the rationale and effi-
cacy of using glutathione-coated PLGA nanoparticles for
efficient brain targeting of pharmaceuticals [18]. Findings in
this study are further evidence to demonstrate the efficacy of
this delivery system to increase the drug permeability to the
brain. Glutathione coating on the surface allows nanopar-
ticles to use glutathione transporters at the BBB to facilitate
the entry of the therapeutic load. For BBB permeable agents
like T3, we speculate that such targeted approach increases
the concentration of the drug at the BBB interface and
increases the probability of absorption than what would be
achieved by simple diffusion or transporter mediated pro-
cess. While glutathione coating can be partially responsible
for greater efficacy of T3-BTNPs over T3-NPs in MCAO
model, an additional mechanism can also be operative.
Glutathione (GSH) serves as an important role in anti-
oxidant defense and its pools are rapidly depleted upon
Fig. 3 Transcriptional activity of T3 nanoparticles. HepG2 cells were
transfected with DR4X2 luciferase reporter, tk-renilla luciferase, and
CMV-TRβ using calcium phosphate transfection method. Cells were
treated with a T3 solution or uncoated/coated T3 nanoparticles at
indicated concentrations. Firefly luciferase determination was made
and normalized by renilla luciferase measurements. The fold change
in the luciferase induction was determined and average of three experi-
ments performed in triplicates has been presented
Fig. 4 Brain tissue uptake of coumarin-6 NPs. Mice were injected
with coumarin-6 NPs (uncoated or coated) i.p. for 1 h. The mice were
sacrificed and brains were excised. Brain tissue was homogenized and
fluorescence was determined (n03)
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onset of reperfusion-related brain injury in stroke [30]. Quite
possibly, our delivery vehicle can help restore the normal
levels of GSH in ischemic brain and offset the redox damage
commonly seen in stroke. Thus, potentially there are dual
mechanisms for improved efficacy of T3-BTNP over T3-NP
in stroke model: increased delivery of T3 and enhancement
of glutathione levels in brain.
Formulation of T3 in PLGA-PEG nanoparticles proved
to be a challenge. Owing to limited solubility of T3 in
acetonitrile, we had to modify our established protocol and
dissolve T3 in DMSO. However, owing to lower volatility
of DMSO, the particle size of the final formulation was
bigger than what is usually obtained in our nano-
precipitation method (50–100 nm). Conceivably, a smaller
nanoparticulate T3 formulation would result in even greater
enhancement of T3 efficacy in stroke by increasing its
uptake and levels at the site of action. Ongoing efforts in
our laboratory are currently focused on alternate means of
generation of smaller nanoparticulate formulations of T3 for
activity in ischemic brain stroke.
Nanoparticulate encapsulation of drug or the coating of
NPs with glutathione does not impede the delivery of the
therapeutic load to cells as was evident in the N2A cell
study. There was no difference in coated versus uncoated
MP delivery of the drug in these cells. While it is not known
if the N2A cells express specific glutathione transporters,
Fig. 5 Neuroprotective activity of T3 nanoparticles in MCAO model
of ischemic brain stroke (n03–6). a Cerebral blood flow measured by
laser Doppler flowmetry. b TTC-stained brain slices from MCAO
mouse model treated with either vehicle, T3 solution, T3 NP, or T3
BTNP. c Determination of tissue infarction in MCAO mouse stroke
model. d Determination of brain edema in MCAO mouse stroke
model. *p<0.05, ***p<0.005
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these transporters are known to exist at the interface of
BBB. The fact the coated NPs demonstrated greater uptake
in the in vivo uptake study while no difference was evident
in the in vitro cell uptake suggests that the N2A cells lack
specific glutathione transporter.
Nanoparticulate encapsulation also does not hinder the
ability of the hormone to modulate gene expression. The
physiological functions of T3 are predominantly reliant on
its ability alter target gene expression. While non-genomic
modulation of nitric oxide levels in vascular endothelial cells
has been suggested as a mechanism of neuroprotective action
of T3, other gene expression modulation related mechanisms
are also likely [17]. Our findings show that T3 encapsulated in
nanoparticles is able to induce the expression of a consensus
TRE driven luciferase reporter in a dose-dependent manner
and at equipotent levels as a solution of T3. Drug-release
studies show that the nanoparticles release T3 at physiological
pH. Our studies show that delivering T3 as nanoparticles does
not alter the physiology of the hormone and functional effects
of T3 are retained in the cells.
Interestingly, formulation of T3 as nanoparticles allowed
the hormone to extend its neuroprotective activity to the
ischemic core. While neuroprotection achieved by T3 solution
was limited to the cortical areas, partial protection of the inner
core of ischemic damage was observed with the T3 nano-
particles. Brain stroke is associated with debilitating neuro-
logical deficits in survivors. Hippocampus, a key region in the
brain involved in cognition and behavior, was partially pro-
tected by the nanoparticles but not by T3 solution. Frequently,
neuroprotective strategies cannot protect against the damage
to ischemic core which is indeed the case seen with T3
solution. Our findings have highlighted the potential for en-
hancement of neuroprotective activity of T3 in the inner
ischemic core. A likely reason for such activity could be the
inherent cellular diffusibility and permeation of the nanopar-
ticles as well as higher local concentrations of T3 achieved as
a result of delivery via nanoparticles. We believe that this
activity will translate into greater improvement in the func-
tional recovery post-brain stroke when using T3 nanoparticles
as opposed to T3 solution.
Several physiological parameters are changed dramatical-
ly in the infarcted area during brain stroke, e.g., pH and
redox changes, all of which will likely change the physi-
ochemical properties of a small molecule drug. Encapsula-
tion of a drug in a nanoparticle affords an efficient means of
circumventing these changes, leading to a more predictable
therapeutic and patient outcome.
Of other great significance is the fact that this study is the
first to report anti-edema action of thyroid hormone in
ischemic brain stroke. Such activity is of immense interest
clinically as rising intracranial pressure due to edema post-
stroke is the prime reason for mortality in stroke. These
findings suggest T3 possesses at least dual activities in
alleviating stroke pathology. Our findings will further sup-
port the development of thyroid hormone pharmacotherapy
in alleviating brain stroke.
Overall, this study has highlighted the feasibility and the
advantage of using nanoparticle formulation of T3 over T3
solution as neuroprotective agent in ischemic brain stroke.
Our findings support strong translational efforts for exploiting
the neuroprotective property of T3 and suggest a means of
achieving the greater efficacy of this hormone in brain stroke.
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